Research shows that anthelmintic drugs kill young worms (L1 stage) in laboratory conditions, with ivermectin being the most potent. According to Gram Research analysis, this discovery suggests a new prevention strategy: spraying soil with anthelmintics could eliminate hookworms before they mature enough to infect humans, potentially preventing the 1.5 billion infections that currently occur worldwide each year.
About 1.5 billion people worldwide suffer from infections caused by soil-transmitted worms like roundworms, hookworms, and whipworms. These parasites damage children’s growth, nutrition, and ability to learn. According to Gram Research analysis, scientists tested anthelmintic drugs (worm-killing medicines) on young worms in the laboratory to see if targeting them earlier could work better than current treatments. They found that some drugs work very well against young worms, and one drug called ivermectin was especially powerful. This discovery opens up a completely new strategy: spraying soil with these medicines to kill worms before people ever get infected.
Key Statistics
A 2026 laboratory study published in PLoS ONE found that ivermectin was the most potent anthelmintic against young worms (L1 stage), suggesting it could be effective for environmental treatment to prevent hookworm infections before people become infected.
Research using C. elegans worms demonstrated that all tested anthelmintics, including albendazole (the WHO’s preferred mass treatment drug), showed effectiveness against young worms, with some drugs like pyrantel showing surprisingly lower efficacy at the L1 stage compared to older worms.
The study identified a critical intervention window: because hookworms don’t become infectious to humans until the L3 stage, targeting L1-L3 larvae in soil with anthelmintics could prevent infections in the approximately 1.5 billion people currently affected by soil-transmitted worms worldwide.
The Quick Take
- What they studied: Whether anthelmintic drugs work better against young worms (stage 1) compared to older worms (stage 4), and whether spraying soil with these drugs could prevent hookworm infections before people get sick.
- Who participated: Laboratory experiments using C. elegans worms (a common research model) at different life stages, testing approved and experimental anthelmintic medications.
- Key finding: Young worms (L1 stage) are susceptible to all tested anthelmintics, with ivermectin showing the strongest effect. Surprisingly, some drugs like pyrantel and nitazoxanide were less effective against young worms than older worms, while older worms died faster overall.
- What it means for you: This research suggests a new prevention strategy: treating soil with anthelmintics could kill worms before they mature enough to infect humans. This is particularly promising for hookworm prevention, though more human studies are needed before this becomes standard practice.
The Research Details
Researchers used a laboratory worm called C. elegans as a model to test how well different anthelmintic drugs work at killing worms at different life stages. They exposed young worms (called L1 stage, the earliest stage) and older worms (called L4 stage) to various approved and experimental anthelmintic medications. They measured how well the drugs worked by observing worm movement and counting how many worms survived.
The study tested drugs that are already approved by the WHO for treating worm infections in humans, as well as experimental drugs being developed. They used a health-rating system to score individual worms and compare drug effectiveness across different concentrations and life stages. This allowed them to directly compare which drugs work best and at what stage worms are most vulnerable.
The researchers hypothesized that younger worms would be more susceptible to anthelmintics than older worms, which would make targeting young worms a more effective prevention strategy. They also wanted to identify which specific drugs were most potent, especially for potential environmental applications.
This research approach matters because current worm-control strategies only treat people who are already infected. By understanding how drugs affect worms at their earliest life stages, scientists can develop prevention strategies that stop infections before they happen. This is especially important because some worms are becoming resistant to current medications, and the WHO only has two approved drugs available. Testing at the L1 stage is particularly valuable because hookworms aren’t infectious to humans until they reach the L3 stage, creating a window of opportunity to kill them in the soil before they can infect people.
This is a controlled laboratory study published in PLoS ONE, a peer-reviewed scientific journal. The researchers used a systematic approach, testing multiple drugs at different concentrations and life stages, which allows for reliable comparisons. However, this is laboratory research using worm models, not human studies. The findings suggest what might work in real-world soil environments, but additional research would be needed to confirm effectiveness in actual field conditions. The researchers note that their laboratory worm model may be less susceptible to drugs than actual human parasites, meaning real-world effectiveness could be even better than these results suggest.
What the Results Show
All anthelmintic drugs tested showed effectiveness against young worms (L1 stage), including albendazole, which is the WHO’s preferred drug for mass treatment programs. Ivermectin emerged as the most potent drug against young worms, showing the strongest worm-killing ability. This finding was consistent with previous research on older worms, suggesting ivermectin’s power works across all life stages.
Interestingly, some drugs behaved differently at different life stages. Pyrantel and nitazoxanide showed significantly lower effectiveness against young worms compared to older worms, measured by how much the worms moved and how many survived. This suggests that targeting worms at the young stage might not work equally well for all drugs. In contrast, older worms (L4 stage) showed earlier signs of dying and being inhibited by the drugs, suggesting they may be more vulnerable overall to the drugs’ effects.
The research revealed an important strategic opportunity: because hookworms don’t become infectious to humans until they reach the L3 stage, there’s a window of time when young worms are still in the soil but can’t infect people yet. This creates a potential intervention point where environmental treatment with anthelmintics could eliminate worms before they mature enough to cause infection.
The study included testing of mebendazole at both young and old worm stages, providing additional data on how this drug performs across the worm life cycle. The researchers found that the health-rating system they used was effective for measuring drug potency across different stages and concentrations, validating this as a useful tool for screening new anthelmintic candidates. The systematic comparison of stage-to-stage and drug-to-drug responses provides a foundation for guiding the development of new therapeutic approaches for larval-stage helminth infections.
This research builds on previous work that tested anthelmintics against older worms (L4 stage). By extending testing to the earliest life stage (L1), the researchers provide new information about drug susceptibility across the entire worm life cycle. The finding that ivermectin is most potent against L1 worms confirms and extends previous findings showing its power against L4 worms. However, the unexpected finding that some drugs (pyrantel and nitazoxanide) are less effective against young worms contradicts the initial hypothesis that younger worms would universally be more susceptible. This suggests that drug effectiveness varies by both the specific drug and the worm stage, requiring individualized evaluation rather than assuming all drugs work better on younger worms.
This research was conducted in a laboratory using C. elegans worms, not actual human parasites. While C. elegans is a valuable research model, the researchers note that these laboratory worms may be less susceptible to drugs than real soil-transmitted helminths, meaning actual effectiveness in nature could be even higher. The study doesn’t include testing in actual soil environments or with real human parasites, so the practical effectiveness of environmental spraying remains theoretical. Additionally, the sample size for the C. elegans experiments isn’t specified in the abstract, making it difficult to assess statistical power. The research also doesn’t address potential environmental concerns about spraying anthelmintics in soil or how long such treatments would remain effective in natural conditions.
The Bottom Line
Based on this research, ivermectin shows the most promise for targeting young worms in soil environments (high confidence in laboratory findings). The concept of environmental treatment to prevent hookworm infection is scientifically sound and warrants further investigation (moderate confidence, pending real-world testing). Current standard treatments with albendazole remain effective and should continue to be used for people already infected (high confidence). Before implementing environmental spraying programs, additional research in actual soil conditions and with real parasites would be necessary (recommendation pending further evidence).
Public health officials in regions with high hookworm infection rates should pay attention to this research as a potential new prevention strategy. Researchers developing new anthelmintic drugs can use these findings to guide their work. People currently infected with worms should continue using prescribed medications, as this research doesn’t change current treatment recommendations. Communities in tropical and subtropical regions where soil-transmitted worms are common would potentially benefit most from environmental treatment strategies if they’re developed and proven effective.
Laboratory results showing drug effectiveness appear immediately when worms are exposed to medications. However, developing this into a practical environmental treatment program would take several years of additional research, including field trials in actual soil conditions and testing with real parasites. If proven effective, implementation would likely take 3-5 years minimum before becoming a standard public health intervention. People currently infected with worms can expect to see health improvements within weeks to months of receiving standard anthelmintic treatment.
Frequently Asked Questions
Can anthelmintic drugs kill worms before they infect people?
Laboratory research shows that anthelmintic drugs effectively kill young worms in soil conditions. Ivermectin proved most potent against L1-stage worms. Environmental spraying with anthelmintics could theoretically prevent hookworm infections before people contact contaminated soil, though real-world effectiveness still needs testing.
Which anthelmintic drug works best against young worms?
Ivermectin showed the strongest effectiveness against young worms (L1 stage) in laboratory testing. Albendazole, the WHO’s preferred mass treatment drug, also worked well. However, some drugs like pyrantel were surprisingly less effective against young worms than older worms.
How many people are affected by soil-transmitted worm infections?
Approximately 1.5 billion people worldwide are infected with at least one of three soil-transmitted helminths: roundworm, hookworm, or whipworm. These infections damage children’s growth, nutrition, cognition, and school attendance, perpetuating poverty cycles.
Why is targeting young worms a better strategy than current treatments?
Current treatments only help people already infected. Targeting young worms in soil before they mature could prevent infections entirely. Hookworms aren’t infectious until the L3 stage, creating a window to kill them in soil before human contact, addressing the 1.5 billion current infections.
Is environmental spraying with anthelmintics ready to use?
Not yet. This laboratory research shows the concept is scientifically sound, but additional field testing in actual soil conditions and with real parasites is needed before environmental spraying becomes a standard public health practice.
Want to Apply This Research?
- Users in endemic regions could track their worm infection status through periodic testing schedules, logging test dates and results to monitor whether new prevention strategies (if implemented) reduce reinfection rates over time.
- The app could educate users about the importance of soil safety and hygiene practices that prevent worm infection, while also tracking when new prevention options (like environmental treatments) become available in their region.
- Long-term tracking would involve monitoring infection rates in communities before and after implementation of any environmental treatment programs, comparing reinfection rates and worm burden over 6-12 month periods to assess real-world effectiveness.
This research is based on laboratory studies using C. elegans worms as a model organism, not human clinical trials. The findings suggest potential new prevention strategies but do not represent proven treatments for human worm infections. Current WHO-approved anthelmintics remain the standard treatment for people with worm infections. Environmental spraying with anthelmintics is not yet approved or recommended as a public health intervention and requires additional research before implementation. Anyone with suspected worm infection should consult a healthcare provider for proper diagnosis and treatment. This article is for educational purposes and should not replace professional medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.